Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis (Q43807560)

27 November 2017

Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis (English)

1 reference

27 November 2017

1 reference

Tsukada H

1

1 reference

27 November 2017

Hirose T

series ordinal

2

1 reference

27 November 2017

Yokoyama A

series ordinal

3

1 reference

27 November 2017

Kurita Y

series ordinal

4

1 reference

27 November 2017

language of work or name

1 reference

1 December 2001

1 reference

European Journal of Cancer

27 November 2017

1 reference

27 November 2017

37

1 reference

27 November 2017

18

1 reference

27 November 2017

2398-2404

1 reference

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Em

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900326-4

7 January 2021

10.1016/S0959-8049(01)00326-4

Identifiers

DOI

1 reference

27 November 2017

1 reference